Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LY01612
- Development stage
- Phase 1
- Lead developer
- Luye Pharma
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
**LY01612** is a pegylated liposomal formulation of **doxorubicin hydrochloride**, a **small molecule** anthracycline **topoisomerase II inhibitor** used as an antineoplastic agent. It encapsulates doxorubicin in liposomes to improve pharmacokinetics, reduce toxicity, and enhance tumor targeting compared to conventional doxorubicin. Developed by **Luye Pharma**, it is being evaluated for **advanced breast cancer** and likely other solid tumors, with bioequivalence demonstrated to **Caelyx** (Doxil) in Chinese patients via studies measuring free and encapsulated doxorubicin concentrations.[3][4][10][15]
02
Targets
TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on LY01612.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LY01612.